MAMohammad Mehdi Amiri

Mohammad Mehdi Amiri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohammad Mehdi Amiri has a total of 169 co-authors. Here are the top co-authors by number of shared publications:

  • Fazel Shokri

    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

    38 shared publications
  • Mahmood Jeddi-Tehrani

    Monoclonal Antibody Research Center, Avicenna Research Institute, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran

    25 shared publications
  • Forough Golsaz-Shirazi

    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

    22 shared publications
  • Jalal Khoshnoodi

    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

    19 shared publications
  • Tannaz Bahadori

    Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

    16 shared publications
  • Mahmood Jeddi-Tehrani

    Monoclonal Antibody Research Center, Avicenna Research Institute, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran

    15 shared publications

Latest Publications

  • Open Access

    Hypertension, Lifestyle Factors, and Breast Cancer Outcomes: A Decade-Long Retrospective Cohort Study

    by Masoud Hassanzadeh Makoui, Reza Hassanzadeh Makoui, Shiva Fekri, Negar Ansari, Fazel Shokri, Mohammad Mehdi Amiri, Lobat Geranpayeh

    Background & Objective: Breast cancer is the second leading cause of cancer-related mortality in women and is influenced by genetic, environmental, and lifestyle factors. This study aimed to evaluate the prevalence of risk factors in breast cancer patients and their association with disease progression and survival. Materials & Methods: A retrospective ...

  • Comparative assessment of four virus neutralization assays for detection of SARS-CoV-2 neutralizing antibodies

    by Faezeh Maghsood, Navid Dashti, Tannaz Bahadori, Forough Golsaz-Shirazi, Christiane Moog, Mohammad Mehdi Amiri, Fazel Shokri


  • Production and characterization of pertussis toxin specific monoclonal and polyclonal antibodies: Implication for toxin purification and detection

    by Danyal Imani, Tannaz Bahadori, Maryam Mobini, Mohammad Ali Judaki, Mahmood Jeddi-Tehrani, Mohammad Mehdi Amiri, Fazel Shokri

  • Production and characterization of monoclonal antibodies against hepatitis B e-antigen and their potential application for development of HBeAg detection ELISA

    by Zeinab Behroozi, Danesh Hassani, Maryam Mobini, Tannaz Bahadori, Kiana Peyghami, Mohammad Ali Judaki, Jalal Khoshnoodi, Mohammad Mehdi Amiri, Forough Golsaz-Shirazi, Fazel Shokri


  • Immunogenicity and Protective Efficacy of an Acellular Pertussis Vaccine Candidate in in a Murine Model

    by Danyal Imani, Tannaz Bahadori, Mohammad Ali Judaki, Maryam Mobini, Mahmood Jeddi-Tehrani, Mohammad Mehdi Amiri, Fazel Shokri

    Acellular pertussis vaccines (aPVs) have been developed as an alternative to whole-cell pertussis vaccines (wPVs) because of their similar efficacy but reduced reactogenicity. The aPV contains 3 or more immunogenic components of Bordetella pertussis. We aimed to evaluate the immunogenicity and protective potency of an aPV vaccine produced in our laboratory consisting of pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN) in mice. The aPV components were produced and purified from the supernatant and pellet of the bacterial culture. Two doses of the formulated vaccine, in parallel with two commercial vaccines, were administered intraperitoneally to mice at 3-week intervals. Antibody titers against aPV antigens were measured by enzyme-linked immunosorbent assay (ELISA) after primary and booster vaccinations. To assess the protective efficacy, an intranasal challenge with a live pathogenic B pertussis strain was conducted 2 weeks after the booster vaccination, and bacterial counts (colony-forming units [CFUs]) in the lungs were determined 2 hours and 10 days after the challenge. The results demonstrated a significant increase in antibody titers against all pertussis antigens in the serum of the vaccinated groups compared with the negative control group, following both the primary and booster doses. No significant differences were observed between our formulation and the commercial vaccines. Furthermore, the CFU results after the challenge showed complete eradication of infection 10 days after the challenge in all immunized groups, in contrast to the control group. Our aPV formulation, the first aPV candidate developed in Iran, exhibits immunogenicity and protective efficacy comparable to those of commercial vaccines. Further investigation of human subjects is warranted.

  • Clinico-Pathological and Prognostic Significance of a Combination of Tumor Biomarkers in Iranian Patients With Breast Cancer

    by Masoud Hassanzadeh Makoui, Maryam Mobini, Shiva Fekri, Lobat Geranpayeh, Hedieh Moradi Tabriz, Zahra Madjd, Elham Kalantari, Maryam Hosseini, Mostafa Hosseini, Forough Golsaz-Shirazi, et al.


  • Comparison of different transient gene expression systems for the production of a new humanized anti-HER2 monoclonal antibody (Hersintuzumab)

    by Ali Roshani, Mehdi Mohammadi, Tannaz Bahadori, Hengameh Ahmadi Zare, Mohammad Ali Judaki, Maryam Mobini, Forough Golsaz-Shirazi, Mahmood Jeddi-Tehrani, Mohammad Mehdi Amiri, Fazel Shokri

    Background Producing therapeutic proteins can be done quickly and on a large scale through Transient Gene Expression (TGE). Chinese hamster ovary (CHO) cell lines are commonly used to achieve this. Although there are few comparative studies, TGE has been observed in suspension-adapted CHO cells. Objectives We tested TGE’s effectiveness in DG-44, CHO-S, and ExpiCHO-S cell lines with four transfection reagents. Methods A design of experiments (DoE) was followed to optimize transfection using a recombinant monoclonal antibody (mAb) construct. To evaluate the efficacy, flow cytometry and ELISA were used. Feeding strategies and temperature shifts were implemented to enhance transfection effectiveness. The quality of the mAb was assessed through ELISA, SDS-PAGE, and proliferation inhibition assays. Results We adapted all cell lines to grow in suspension using a serum-free medium. Our findings from flow cytometry and ELISA tests indicate that PEI and Pmax reagents had a higher rate of transfection and mAb production than the ExpiCHO commercial transfection reagent. While DG-44 cells had better transfection efficiency than CHO-S and ExpiCHO-S, there was no significant difference between CHO-S and ExpiCHO-S. Our TGE system was more productive at 32 °C than at 37 °C. In the optimized TGE of Pmax-based transfection in DG-44 at 37 and 32 °C, the production level of mAb was more than half of the amount of the commercial ExpiCHO-S expression system. Still, the number of transfected cells was three times higher, making it more efficient. The purified mAb from all transfected cell lines had similar structural and functional properties under different conditions. Conclusion Our research shows that using Pmax and DG-44 cells in the TGE system is a cost-effective and efficient way to produce humanized monoclonal antibodies. We discovered that this method outperforms the ExpiCHO-S kit. Graphical abstract


  • Novel mouse monoclonal antibodies against Bordetella pertussis pertactin antigen with versatile applications

    by Danyal Imani, Tannaz Bahadori, Sedighe Ghourchian, Forough Golsaz-Shirazi, Masoumeh Douraghi, Mahmood Jeddi-Tehrani, Mohammad Mehdi Amiri, Fazel Shokri


  • Open Access

    Prophylactic vs. Therapeutic Effect of Probiotics on the Inflammation Mediated by the NF-κB Pathway in Inflammatory Bowel Conditions

    by Saeideh Najafi, Fattah Sotoodehnejadnematalahi, Mohammad Mehdi Amiri, Mohammad Reza Pourshafie, Mahdi Rohani

    Probiotic supplements consumed adequately at the proper time can affect health by modulating inflammatory pathways in gastrointestinal epithelial cells and modifying the resultant inflammatory response. The current study applied in vitro models to investigate the effectiveness of probiotics in modulating inflammatory pathways and altering inflammatory gene expression in gastrointestinal epithelial cells, with the ultimate goal of promoting probiotic consumption as a therapeutic and preventive measure for chronic inflammatory bowel conditions. HT-29 cells were treated with Gram-negative bacteria to evaluate the changes in pathways related to inflammation activities before and after treatment with a Lactobacillus spp. cocktail (L. plantarum, L. rhamnosus, L. brevis, and L. ruteri) and a Bifidobacterium spp. cocktail (B. bifidum, B. langum, and B. breve) using the real-time PCR method and ELISA for IL-1β and IL-6 as pro-inflammatory cytokines. The results showed that the expression of NF-κB signaling pathway genes and IL-1β and IL-6 cytokines increased after exposure to Gram-negative components. In contrast, all probiotic combinations significantly decreased the expression of genes and the secretion of cytokines. However, this decrease was significantly smaller in cells that underwent probiotic treatment after inflammation induction. In addition, cocktails containing combined Lactobacillus and Bifidobacterium demonstrated robust anti-inflammatory activity relative to solo cocktails. Our observations confirm that probiotic consumption could positively impact inflammatory conditions and alleviate inflammatory symptoms; they can be particularly effective as a preventive measure. Our study provides preliminary evidence to support the lifetime consumption of probiotics.


  • Novel Monoclonal Antibodies Specific for Human Ki67 and P53 Tumor Markers in Breast Cancer Tissue Samples

    by Masoud Hassanzadeh Makoui, Maryam Mobini, Jalal Khoshnoodi, Tannaz Bahadori, Forough Golsaz-Shirazi, Hedieh Moradi Tabriz, Zahra Madjd, Mahmood Jeddi-Tehrani, Amir-Hassan Zarnani, Mohammad Mehdi Amiri, et al.

    Background: Ki67 and P53 are important diagnostic and prognostic biomarkers expressed in several cancers. The current standard method for evaluating Ki67 and P53 in cancer tissues is immunohistochemistry (IHC), and having highly sensitive monoclonal antibodies against these biomarkers is necessary for an accurate diagnosis in the IHC test.Objective: To generate and characterize novel monoclonal antibodies (mAbs) against human Ki67 and P53 antigens for IHC purposes.Methods: Ki67 and P53-specific mAbs were produced by the hybridoma method and screened by enzyme-linked immunosorbent assay (ELISA) and IHC techniques. Selected mAbs were characterized using Western blot and flow cytometry, and their affinities and isotypes were determined by ELISA. Moreover, using the IHC technique in 200 breast cancer tissue samples, we assessed the specificity, sensitivity, and accuracy of the produced mAbs.Results: Two anti-Ki67 (2C2 and 2H1) and three anti-P53 mAbs (2A6, 2G4, and 1G10) showed strong reactivity to their target antigens in IHC. The selected mAbs were also able to recognize their targets by flow cytometry as well as Western blotting using human tumor cell lines expressing these antigens. The specificity, sensitivity, and accuracy calculated for clone 2H1 were 94.2%, 99.0%, and 96.6%, and for clone 2A6 were 97.3%, 98.1%, and 97.5%, respectively. Using these two monoclonal antibodies, we found a significant correlation between Ki67 and P53 overexpression and lymph node metastasis in patients with breast cancer.Conclusion: The present study showed that the novel anti-Ki67 and anti-P53 mAbs could recognize their respective antigens with high specificity and sensitivity and therefore can be used in prognostic studies.